Latest Breaking News On - Evaluating glofitamab - Page 1 : comparemela.com

Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.

Mabthera rituxinLevi garrawayKrish patelLymphoma programSwedish cancer institute in seattleGlobal product development at rocheEvaluating glofitamabCombination with gemcitabineParticipants withRefractory diffuse largeb cellSwedish cancer instituteGlobal product development